Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Evotec SE
Merck & Co. And Gates Foundation Drug Hunters Hopeful Of A TB Breakthrough
The Bill & Melinda Gates Foundation has brought together big pharma companies and academic institutes in a non-profit venture to find new drugs to improve tuberculosis treatment. One participant, Merck & Co, talks to Scrip about two promising novel molecules that it discovered for the Foundation’s Medical Research Institute to develop.
The Busiest Dealmakers Of 2022
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
GSK Phase II Win Offers Hope For TB Breakthrough
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.
Boehringer Pledges Another €30m To Tackle AMR
The three companies have joined forces to launch Aurobac Therapeutics, combining their respective strengths to develop a precision approach to treating infections.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Bionamics GmbH
- Cyprotex PLC
- DeveloGen AG
- Euprotec Ltd
- Evotec AG
- Evotec BioSystems GmbH
- Evotec Neurosciences GmbH
- Evotec BioSystems AG
- Just Biotherapeutics, Inc.
- Kinaxo Biotechnologies
- Compound Focus
- Just – Evotec Biologics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.